P. Ruggenenti

发表

Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease.

L. Antiga, G. Remuzzi, B. Ene-Iordache, 2005, Kidney international.

Sirolimus therapy to halt the progression of ADPKD.

L. Antiga, M. Cortinovis, N. Perico, 2010, Journal of the American Society of Nephrology : JASN.

Reducing polycystic liver volume in ADPKD: effects of somatostatin analogue octreotide.

L. Antiga, G. Remuzzi, A. Remuzzi, 2010, Clinical journal of the American Society of Nephrology : CJASN.

Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial

Luca Antiga, Andrea Remuzzi, Paolo Brambilla, 2013, The Lancet.

Sirolimus Versus Cyclosporine Therapy Increases Circulating Regulatory T Cells, But Does Not Protect Renal Transplant Patients Given Alemtuzumab Induction From Chronic Allograft Injury

N. Perico, G. Remuzzi, V. D’Agati, 2007, Transplantation.

Long‐term outcome of renal transplantation from octogenarian donors: A multicenter controlled study

G. Remuzzi, P. Ruggenenti, A. Perna, 2017, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Time to abandon microalbuminuria?

G. Remuzzi, P. Ruggenenti, 2006, Kidney international.

Young women with polycystic liver disease respond best to somatostatin analogues: a pooled analysis of individual patient data.

F. Nevens, V. Torres, P. Ruggenenti, 2013, Gastroenterology.

Cross sectional longitudinal study of spot morning urine protein:creatinine ratio, 24 hour urine protein excretion rate, glomerular filtration rate, and end stage renal failure in chronic renal disease in patients without diabetes

G. Remuzzi, F. Gaspari, P. Ruggenenti, 1998, BMJ.

Blood pressure, proteinuria, and phosphate as risk factors for progressive kidney disease: a hypothesis.

G. Remuzzi, P. Ruggenenti, D. Brancaccio, 2013, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Mycophenolate mofetil versus azathioprine for prevention of acute rejection in renal transplantation (MYSS): a randomised trial

B. Dimitrov, N. Perico, G. Remuzzi, 2004, The Lancet.

Measurable urinary albumin predicts cardiovascular risk among normoalbuminuric patients with type 2 diabetes.

G. Remuzzi, B. Ene-Iordache, F. Gaspari, 2012, Journal of the American Society of Nephrology : JASN.

Prevention and treatment of diabetic renal disease in type 2 diabetes: the BENEDICT study.

G. Remuzzi, P. Ruggenenti, M. Macía, 2006, Journal of the American Society of Nephrology : JASN.

Preventing microalbuminuria in type 2 diabetes.

G. Remuzzi, B. Ene-Iordache, F. Gaspari, 2004, The New England journal of medicine.

Chronic Renal Diseases: Renoprotective Benefits of ReninAngiotensin System Inhibition

Giuseppe Remuzzi, Piero Ruggenenti, Norberto Perico, 2002, Annals of Internal Medicine.

Selective impairment of gene expression and assembly of nephrin in human diabetic nephropathy.

G. Remuzzi, R. Kalluri, A. Benigni, 2004, Kidney international.

Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts.

Laura E. Clark, M. Landray, F. Kronenberg, 2011, Kidney international.

Nephropathy in Patients with Type 2 Diabetes

Giuseppe Remuzzi, Piero Ruggenenti, Arrigo Schieppati, 2002 .

Clinical practice. Nephropathy in patients with type 2 diabetes.

Giuseppe Remuzzi, Piero Ruggenenti, Arrigo Schieppati, 2002, The New England journal of medicine.

The kidney and cardiovascular risk – Implications for management: A consensus statement from the European Society of Hypertension

G. Mancia, L. Ruilope, A. de la Sierra, 2007, Blood pressure.

What blood-pressure level provides greatest renoprotection in patients with diabetic nephropathy and hypertension?

G. Remuzzi, P. Ruggenenti, 2006, Nature Clinical Practice Nephrology.

Functional Magnetic Resonance Imaging Versus Kidney Biopsy to Assess Response to Therapy in Nephrotic Syndrome: A Case Report

G. Remuzzi, A. Remuzzi, P. Brambilla, 2020, Kidney medicine.

Thrice-Weekly In-Center Nocturnal Hemodialysis: An Effective Strategy to Optimize Chronic Dialysis Therapy

G. Remuzzi, P. Ruggenenti, P. Cravedi, 2009, The International journal of artificial organs.

In chronic nephropathies prolonged ACE inhibition can induce remission: dynamics of time-dependent changes in GFR. Investigators of the GISEN Group. Gruppo Italiano Studi Epidemiologici in Nefrologia.

G. Remuzzi, M. Salvadori, C. Zoccali, 1999, Journal of the American Society of Nephrology : JASN.

Chronic Nephropathies: Individual Risk for Progression to End-Stage Renal Failure as Predicted by an Integrated Probabilistic Model

B. Dimitrov, R. Stefanov, G. Remuzzi, 2003, Nephron Clinical Practice.

Plasma clearance of nonradioactive iohexol as a measure of glomerular filtration rate.

N. Perico, G. Remuzzi, F. Gaspari, 1995, Journal of the American Society of Nephrology : JASN.

ACE inhibition versus angiotensin receptor blockade: which is better for renal and cardiovascular protection?

G. Remuzzi, G. Laverman, P. Ruggenenti, 2004, Journal of the American Society of Nephrology : JASN.

Are "routine" clinical and laboratory examinations of any help in the treatment of chronic hemodialysis patients?

G. Remuzzi, P. Ruggenenti, G. Mecca, 1987, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Effects of dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibition, and blood pressure control on chronic, nondiabetic nephropathies. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN).

G. Remuzzi, P. Ruggenenti, A. Perna, 1998, Journal of the American Society of Nephrology : JASN.

Sirolimus to replace calcineurin inhibitors? Too early yet

G. Remuzzi, P. Ruggenenti, P. Cravedi, 2009, The Lancet.

Non-proteinuric pathways in loss of renal function in patients with type 2 diabetes.

E. Porrini, P. Ruggenenti, A. D. de Vries, 2015, The lancet. Diabetes & endocrinology.

Glomerular size-selective dysfunction in NIDDM is not ameliorated by ACE inhibition or by calcium channel blockade.

G. Remuzzi, A. Remuzzi, P. Ruggenenti, 1999, Kidney international.

Preventing Left Ventricular Hypertrophy by ACE Inhibition in Hypertensive Patients With Type 2 Diabetes

G. Remuzzi, B. Ene-Iordache, P. Ruggenenti, 2008, Diabetes Care.

Achieving remission of proteinuria in childhood CKD

G. Remuzzi, P. Ruggenenti, P. Cravedi, 2017, Pediatric Nephrology.

Conversion from Brand-Name Neoral to the Generic Ciqorin in Stable Renal Transplant Recipients

N. Perico, G. Remuzzi, F. Gaspari, 2016, Nephron.

Role of remission clinics in the longitudinal treatment of CKD.

G. Remuzzi, Sanjib K. Sharma, P. Ruggenenti, 2008, Journal of the American Society of Nephrology : JASN.

The rate of progression of renal disease may not be slower in women compared with men: a patient-level meta-analysis.

C. Schmid, A. Levey, G. Remuzzi, 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Long-Term Outcome of Renal Transplantation from Older Donors

B. Dimitrov, G. Remuzzi, P. Ruggenenti, 2006 .

C5 Convertase Blockade in Membranoproliferative Glomerulonephritis: A Single-Arm Clinical Trial.

G. Remuzzi, F. Gaspari, D. Santoro, 2019, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Insulin resistance and proliferative retinopathy: a cross-sectional, case-control study in 115 patients with type 2 diabetes.

B. Dimitrov, G. Remuzzi, A. Tiengo, 2004, The Journal of clinical endocrinology and metabolism.

Glucose-induced changes in renal haemodynamics in proteinuric Type 1 (insulin-dependent) diabetic patients: inhibition by acetylsalicilic acid infusion

G. Remuzzi, K. Earle, P. Ruggenenti, 1993, Diabetologia.

Glomerular resistances predict long-term GFR decline in type 2 diabetic patients without overt nephropathy: a longitudinal subgroup analysis of the DEMAND trial

G. Remuzzi, F. Gaspari, P. Ruggenenti, 2021, Acta Diabetologica.

Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephRopathy in TYpe 2 diabetic patients with normoalbuminuria (PRIORITY): essential study design and rationale of a randomised clinical multicentre trial

H. Mischak, G. Navis, A. Ortiz, 2016, BMJ Open.

Renal and Systemic Effects of Calorie Restriction in Patients With Type 2 Diabetes With Abdominal Obesity: A Randomized Controlled Trial

G. Remuzzi, M. Trillini, P. Ruggenenti, 2016, Diabetes.

In type-2 diabetics with abdominal obesity, hyperfiltration is a risk factor for accelerated GFR decline and nephropathy. In this academic, single-center, parallel-group, Prospective, Randomized, Open-label, Blinded Endpoint (PROBE) trial (ClinicalTRials.gov number: NCT01213212), consenting >18-year

G. Remuzzi, M. Trillini, P. Ruggenenti, 2016 .

Nephrotic-range proteinuria in type 2 diabetes: Effects of empagliflozin on kidney disease progression and clinical outcomes

B. Zinman, G. Remuzzi, C. Wanner, 2021, EClinicalMedicine.

Ramipril prolongs life and is cost effective in chronic proteinuric nephropathies.

G. Remuzzi, P. Ruggenenti, E. Pagano, 2001, Kidney international.

ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy.

G. Remuzzi, P. Ruggenenti, A. Perna, 2001, Journal of the American Society of Nephrology : JASN.

Renin–angiotensin system: Meta-analyses can misdirect decisions on treatment

G. Remuzzi, P. Ruggenenti, 2013, Nature Reviews Nephrology.

Effects of Combined Ezetimibe and Simvastatin Therapy as Compared With Simvastatin Alone in Patients With Type 2 Diabetes

G. Remuzzi, B. Ene-Iordache, P. Ruggenenti, 2010, Diabetes Care.

A Home-Treatment Algorithm Based on Anti-inflammatory Drugs to Prevent Hospitalization of Patients With Early COVID-19: A Matched-Cohort Study (COVER 2)

N. Perico, G. Remuzzi, P. Ruggenenti, 2021, Frontiers in Medicine.

Nephropathy in NIDDM Patients, Predictors of Outcome

G. Remuzzi, P. Ruggenenti, 2000 .

Nephropathy of type-2 diabetes mellitus.

G. Remuzzi, P. Ruggenenti, 1998, Journal of the American Society of Nephrology : JASN.

Long-Term Kidney and Systemic Effects Of Calorie Restriction in Overweight or Obese Type 2 Diabetic Patients (C.Re.S.O. 2 Randomized Controlled Trial).

G. Remuzzi, F. Gaspari, M. Trillini, 2022, Diabetes research and clinical practice.

Proteinuria should be used as a surrogate in CKD

G. Remuzzi, P. Ruggenenti, P. Cravedi, 2012, Nature Reviews Nephrology.

Impact of blood pressure control and angiotensin-converting enzyme inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: a post hoc analysis of the BENEDICT trial.

G. Remuzzi, B. Ene-Iordache, P. Ruggenenti, 2006, Journal of the American Society of Nephrology : JASN.

Angiotensin-converting enzyme inhibition and angiotensin II antagonism in nondiabetic chronic nephropathies.

P. Ruggenenti, 2004, Seminars in nephrology.

Antiproteinuric Effect of Chemokine C-C Motif Ligand 2 Inhibition in Subjects with Acute Proliferative Lupus Nephritis

G. Remuzzi, S. Bombardieri, P. Ruggenenti, 2011, American Journal of Nephrology.

Angiotensin converting enzyme inhibition improves glomerular size-selectivity in IgA nephropathy.

G. Remuzzi, A. Remuzzi, P. Ruggenenti, 1991, Kidney international.

Low-Dose RATG with or without Basiliximab in Renal Transplantation: A Matched-Cohort Observational Study

G. Remuzzi, P. Ruggenenti, G. Rota, 2015, American Journal of Nephrology.

Multicentre prospective validation of a urinary peptidome-based classifier for the diagnosis of type 2 diabetic nephropathy.

D. Maahs, H. Mischak, G. Navis, 2014, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Preventing microalbuminuria with benazepril, valsartan, and benazepril–valsartan combination therapy in diabetic patients with high-normal albuminuria: A prospective, randomized, open-label, blinded endpoint (PROBE) study

G. Remuzzi, F. Gaspari, M. Trillini, 2021, PLoS medicine.

Effect on blood pressure of combined inhibition of endothelin-converting enzyme and neutral endopeptidase with daglutril in patients with type 2 diabetes who have albuminuria: a randomised, crossover, double-blind, placebo-controlled trial.

G. Remuzzi, A. Benigni, I. M. van der Meer, 2013, The lancet. Diabetes & endocrinology.

Slowing the progression of diabetic nephropathy.

G. Remuzzi, P. Ruggenenti, 1993, New England Journal of Medicine.

Prognosis of diabetic nephropathy: how to improve the outcome.

G. Remuzzi, P. Ruggenenti, 1998, Diabetes research and clinical practice.

Intensified inhibition of renin-angiotensin system: A way to improve renal protection?

G. Remuzzi, P. Ruggenenti, P. Cravedi, 2007, Current hypertension reports.

Does remission of renal disease associated with antihypertensive treatment exist?

G. Remuzzi, P. Ruggenenti, P. Cravedi, 2007, Current hypertension reports.

Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies.

G. Remuzzi, A. Remuzzi, P. Ruggenenti, 2003, Kidney international.

Nephropathy of type 1 and type 2 diabetes: diverse pathophysiology, same treatment?

G. Remuzzi, P. Ruggenenti, 2000, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Chronic proteinuric nephropathies. II. Outcomes and response to treatment in a prospective cohort of 352 patients: differences between women and men in relation to the ACE gene polymorphism. Gruppo Italiano di Studi Epidemologici in Nefrologia (Gisen)

G. Remuzzi, C. Zoccali, P. Ruggenenti, 2000, Journal of the American Society of Nephrology : JASN.

High-performance liquid chromatographic determination of iothalamic acid in human plasma and urine.

G. Remuzzi, F. Gaspari, P. Ruggenenti, 1991, Journal of chromatography.

ACE and SGLT2 inhibitors: the future for non‐diabetic and diabetic proteinuric renal disease

N. Perico, G. Remuzzi, P. Ruggenenti, 2017, Current opinion in pharmacology.

Misleading meta‐analysis: a need to look beyond the headlines

G. Remuzzi, N. Chaturvedi, R. Bilous, 2007, Diabetic medicine : a journal of the British Diabetic Association.

Angiotensin-converting enzyme inhibition or angiotensin receptor blockade in hypertensive diabetics?

G. Remuzzi, P. Ruggenenti, Gozewÿn Laverman, 2003, Current hypertension reports.

Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria

Giuseppe Remuzzi, Giulia Gherardi, Carmine Zoccali, 1999, The Lancet.

The way to cardio-renal protection in non-diabetic chronic nephropathies

G. Remuzzi, P. Ruggenenti, M. Negri, 2004 .

Inhibitors to Prevent End-Stage Renal Disease : When to Start and Why Possibly Never to Stop : A Post Hoc Analysis of the REIN Trial Results

G. Remuzzi, P. Ruggenenti, A. Perna, 2001 .

ACE inhibition improves glomerular size selectivity in patients with idiopathic membranous nephropathy and persistent nephrotic syndrome.

G. Remuzzi, A. Remuzzi, P. Ruggenenti, 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.

A long term, randomized clinical trial to evaluate the effects of ramipril on the evolution of renal function in chronic nephropathies

G. Remuzzi, M. Salvadori, C. Zoccali, 1991 .

Proteinuria: Is the ONTARGET renal substudy actually off target?

G. Remuzzi, P. Ruggenenti, 2009, Nature Reviews Nephrology.

Mycophenolate mofetil versus azathioprine for prevention of chronic allograft dysfunction in renal transplantation: the MYSS follow-up randomized, controlled clinical trial.

G. Remuzzi, B. Ene-Iordache, M. Salvadori, 2007, Journal of the American Society of Nephrology : JASN.

Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. "Gruppo Italiano di Studi Epidemiologici in Nefrologia" (GISEN).

G. Remuzzi, P. Ruggenenti, A. Perna, 1998, Kidney international.

Predicting end-stage renal disease: Bayesian perspective of information transfer in the clinical decision-making process at the individual level.

B. Dimitrov, G. Remuzzi, P. Ruggenenti, 2003, Kidney international.

Strategies for national health care systems in emerging countries: the case of screening and prevention of renal disease progression in Bolivia.

N. Perico, G. Remuzzi, I. Codreanu, 2005, Kidney international. Supplement.

Nitrendipine and enalapril improve albuminuria and glomerular filtration rate in non-insulin dependent diabetes.

G. Remuzzi, P. Ruggenenti, A. Perna, 1996, Kidney international. Supplement.

Reply to ‘Strengths and limitations of estimated and measured GFR’

G. Remuzzi, F. Gaspari, E. Porrini, 2019, Nature Reviews Nephrology.

Nondiabetic Kidney Disease

G. Remuzzi, P. Ruggenenti, P. Cravedi, 2010 .

Safety of Rituximab Compared with Steroids and Cyclophosphamide for Idiopathic Membranous Nephropathy.

G. Remuzzi, J. Wetzels, P. Ruggenenti, 2017, Journal of the American Society of Nephrology : JASN.

Impact of the PPAR-γ2 Pro12Ala Polymorphism and ACE Inhibitor Therapy on New-Onset Microalbuminuria in Type 2 Diabetes: Evidence From BENEDICT

G. Remuzzi, P. Ruggenenti, N. Motterlini, 2009, Diabetes.

Effects of Manidipine and Delapril in Hypertensive Patients With Type 2 Diabetes Mellitus: The Delapril and Manidipine for Nephroprotection in Diabetes (DEMAND) Randomized Clinical Trial

G. Remuzzi, B. Ene-Iordache, F. Gaspari, 2011, Hypertension.

Proteinuria predicts end-stage renal failure in non-diabetic chronic nephropathies. The "Gruppo Italiano di Studi Epidemiologici in Nefrologia" (GISEN).

G. Remuzzi, F. Gaspari, P. Ruggenenti, 1997, Kidney international. Supplement.

Effects of Sevelamer Carbonate in Patients With CKD and Proteinuria: The ANSWER Randomized Trial.

G. Remuzzi, C. Zoccali, M. Trillini, 2019, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Chronic renal disease

G. Remuzzi, P. Ruggenenti, A. Schieppati, 2001, The Lancet.

Long-term Effects of Octreotide on Liver Volume in Patients With Polycystic Kidney and Liver Disease.

G. Remuzzi, P. Ruggenenti, N. Rubis, 2016, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Effect of the urotensin receptor antagonist palosuran on albuminuria in hypertensive patients with type 2 diabetic nephropathy: results from the PROLONG proof-of-concept study

S. Hadjadj, G. Remuzzi, H. Krum, 2008 .

Renal Hemodynamics and Renoprotection

P. Ruggenenti, G. Vidili, R. Faedda, 2008, Nephron Clinical Practice.

Long-term treatment with either enalapril or nitrendipine stabilizes albuminuria and increases glomerular filtration rate in non-insulin-dependent diabetic patients.

G. Remuzzi, M. Campana, P. Ruggenenti, 1994, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Following an initial decline, glomerular filtration rate stabilizes in heart transplant patients on chronic cyclosporine.

N. Perico, G. Remuzzi, P. Ruggenenti, 1994, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Dealing with Renin-Angiotensin Inhibitors, Don’t Mind Serum Creatinine

G. Remuzzi, P. Ruggenenti, 2012, American Journal of Nephrology.

Angiotensin converting enzyme insertion/deletion polymorphism and renoprotection in diabetic and nondiabetic nephropathies.

G. Remuzzi, P. Ruggenenti, P. Bettinaglio, 2008, Clinical journal of the American Society of Nephrology : CJASN.

Latest treatment strategies for membranous nephropathy

G. Remuzzi, P. Ruggenenti, P. Cravedi, 2007, Expert opinion on pharmacotherapy.

Mycophenolate mofetil versus azathioprine in kidney transplant recipients on steroid-free, low-dose cyclosporine immunosuppression (ATHENA): A pragmatic randomized trial

G. Remuzzi, F. Gaspari, M. Marasà, 2021, PLoS medicine.

Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome.

M. Rudnicki, G. Capasso, R. Pollastro, 2014, Journal of the American Society of Nephrology : JASN.

Old Donors for Kidney Transplantation: How Old?

G. Remuzzi, P. Ruggenenti, P. Cravedi, 2010, Gerontology.

Glomerular hyperfiltration

N. Perico, G. Remuzzi, A. Remuzzi, 2022, Nature Reviews Nephrology.

Bergamo and Covid-19: How the Dark Can Turn to Light

C. la Vecchia, N. Perico, G. Remuzzi, 2020, Frontiers in Medicine.

Preimplantation Histological Score Associates with 6-Month GFR in Recipients of Perfused, Older Kidney Grafts: Results from a Pilot Study

G. Remuzzi, P. Ruggenenti, A. Perna, 2021, Nephron.

Long-Term Outcomes of Kidney Transplants from Older/Marginal Donors: A Cohort Study

B. Bikbov, N. Perico, G. Remuzzi, 2021, Nephron.

Dual Kidney Transplantation

P. Ruggenenti, P. Cravedi, A. Angeletti, 2017 .

Thrombotic microangiopathy, hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: Rare manifestations of Russell’s viper (Daboia russelii) envenoming in Sri Lanka

G. Remuzzi, P. Ruggenenti, M. Noris, 2021 .

Haemolytic—Uraemic Syndrome and Thrombotic Thrombocytopenic Purpura

G. Remuzzi, P. Ruggenenti, 1993 .

Anti-Phospholipase A2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy.

G. Remuzzi, A. Benigni, F. Gaspari, 2015, Journal of the American Society of Nephrology : JASN.

Calcium channel blockers protect transplant patients from cyclosporine-induced daily renal hypoperfusion.

N. Perico, G. Remuzzi, A. Benigni, 1993, Kidney international.

Effect of the Urotensin Receptor Antagonist Palosuran in Hypertensive Patients With Type 2 Diabetic Nephropathy

S. Hadjadj, G. Remuzzi, H. Krum, 2010, Hypertension.

A Multidrug, Antiproteinuric Approach to Alport Syndrome: A Ten-Year Cohort Study

G. Remuzzi, F. Gaspari, D. Roccatello, 2015, Nephron.

DISEASE OF THE MONTH

G. Remuzzi, P. Ruggenenti, S. Bruno, 2003 .

Post-transplant renal artery stenosis: the hemodynamic response to revascularization.

G. Remuzzi, A. Remuzzi, P. Ruggenenti, 2001, Kidney international.

Chronic Allograft Nephropathy

P. Ruggenenti, 2005 .

Redefining the Role of Donor Biopsies in the Process of Kidney Graft Assessment

G. Remuzzi, P. Ruggenenti, Camillo Carrara, 2021, Nephron.

Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial.

G. Nijpels, F. Rutters, H. Mischak, 2020, The lancet. Diabetes & endocrinology.

Characteristics of high‐ and low‐risk individuals in the PRIORITY study: urinary proteomics and mineralocorticoid receptor antagonism for prevention of diabetic nephropathy in Type 2 diabetes

G. Nijpels, F. Rutters, H. Mischak, 2018, Diabetic medicine : a journal of the British Diabetic Association.

DOPPLER ULTRASONOGRAPHY IN POSTTRANSPLANT RENAL ARTERY STENOSIS: A RELIABLE TOOL FOR ASSESSING EFFECTIVENESS OF REVASCULARIZATION?

G. Remuzzi, P. Ruggenenti, S. Bruno, 2003, Transplantation.

PPARγ2 P12A polymorphism and albuminuria in patients with type 2 diabetes: a meta-analysis of case-control studies.

G. Remuzzi, M. Copetti, P. Ruggenenti, 2011, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Prevention and treatment of pregnancy-associated hypertension: what have we learned in the last 10 years?

G. Remuzzi, P. Ruggenenti, 1991, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Effects of Combined Ezetimibe and Simvastatin Therapy as Compared With Simvastatin Alone in Patients With Type 2 Diabetes: A Prospective Randomized Double-Blind Clinical Trial

G. Remuzzi, P. Ruggenenti, A. Perna, 2010, Diabetes Care.

In Kidney Transplant Patients, Alemtuzumab but Not Basiliximab/Low-Dose Rabbit Anti-Thymocyte Globulin Induces B Cell Depletion and Regeneration, Which Associates with a High Incidence of De Novo Donor-Specific Anti-HLA Antibody Development

N. Perico, G. Remuzzi, F. Gaspari, 2013, The Journal of Immunology.

Pancreas and kidney/pancreas transplants: experimental medicine or real improvement?

G. Remuzzi, P. Ruggenenti, S. Mauer, 1994, The Lancet.

Oral acetyl-L-carnitine therapy and insulin resistance.

G. Remuzzi, I. M. van der Meer, P. Ruggenenti, 2010, Hypertension.

Dreaming of normoglycaemia with fewer diet restrictions.

G. Remuzzi, P. Ruggenenti, 2014, The Lancet Diabetes and Endocrinology.

Combined neprilysin and RAS inhibition for the failing heart: straining the kidney to help the heart?

G. Remuzzi, P. Ruggenenti, 2015, European journal of heart failure.

Primary prevention of renal failure in diabetic patients: the Bergamo Nephrologic Diabetes Complication Trial.

G. Remuzzi, P. Ruggenenti, 1998, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial.

Debra F. Weinstein, Michael G. Miller, M. A. Ferreira, 2019, Lancet.

Impact of a Complement Factor H Gene Variant on Renal Dysfunction, Cardiovascular Events, and Response to ACE Inhibitor Therapy in Type 2 Diabetes

G. Remuzzi, A. Benigni, P. Ruggenenti, 2019, Front. Genet..

Progression, Remission and Regression of Chronic Renal Diseases

G. Remuzzi, P. Ruggenenti, Monica Cortinovis, 2016, Nephron.

The diagnosis of renal involvement in non‐insulin-dependent diabetes mellitus

G. Remuzzi, P. Ruggenenti, 1997, Current opinion in nephrology and hypertension.

Case Report: Effects of Anti-SARS-CoV-2 Convalescent Antibodies Obtained With Double Filtration Plasmapheresis

G. Remuzzi, P. Ruggenenti, M. Noris, 2021, Frontiers in Immunology.

β-cell transplantation for diabetes therapy – Authors' reply

G. Remuzzi, A. Remuzzi, P. Ruggenenti, 2008, The Lancet.

Increased nitric oxide formation in recurrent thrombotic microangiopathies: a possible mediator of microvascular injury.

G. Remuzzi, F. Gaspari, P. Ruggenenti, 1996, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Moderate salt restriction with or without paricalcitol in type 2 diabetes and losartan-resistant macroalbuminuria (PROCEED): a randomised, double-blind, placebo-controlled, crossover trial.

G. Remuzzi, F. Gaspari, M. Trillini, 2018, The Lancet Diabetes and Endocrinology.

Titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy.

G. Remuzzi, P. Ruggenenti, P. Cravedi, 2007, Clinical journal of the American Society of Nephrology : CJASN.

Angiotensin-converting enzyme inhibitor therapy for non-diabetic progressive renal disease

G. Remuzzi, P. Ruggenenti, 1997, Current opinion in nephrology and hypertension.

Sequential monitoring of urine-soluble interleukin 2 receptor and interleukin 6 predicts acute rejection of human renal allografts before clinical or laboratory signs of renal dysfunction.

N. Perico, G. Remuzzi, P. Ruggenenti, 1997, Transplantation.

Nature and extent of glomerular injury induced by cyclosporine in heart transplant patients.

N. Perico, G. Remuzzi, A. Remuzzi, 1991, Kidney international.

Early experience with dual kidney transplantation in adults using expanded donor criteria. Double Kidney Transplant Group (DKG).

B. Brenner, G. Remuzzi, P. Ruggenenti, 1999, Journal of the American Society of Nephrology : JASN.

Optimizing Allocation of Kidneys from Older Donors

G. Remuzzi, P. Ruggenenti, P. Cravedi, 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Outcome of renal transplantation from very old donors.

G. Remuzzi, P. Ruggenenti, N. Motterlini, 2009, The New England journal of medicine.

One or two marginal organs for kidney transplantation?

N. Perico, G. Remuzzi, P. Ruggenenti, 2002, Transplantation proceedings.

Renal transplantation: single or dual for donors aging > or =60 years?

G. Remuzzi, P. Ruggenenti, 2000, Transplantation.

Thrombotic thrombocytopenic purpura: evidence that infusion rather than removal of plasma induces remission of the disease.

G. Remuzzi, P. Ruggenenti, M. Galbusera, 1993, American journal of kidney diseases : the official journal of the National Kidney Foundation.

At the peak of Covid-19 age and disease severity but not comorbidities are predictors of mortality. Covid-19 burden in Bergamo, Italy.

A. Gavazzi, G. Remuzzi, M. Senni, 2020, Panminerva medica.

Spironolactone Plus Full-Dose ACE Inhibition in Patients with Idiopathic Membranous Nephropathy and Nephrotic Syndrome: Does It Really Work?

G. Remuzzi, P. Ruggenenti, P. Cravedi, 2010, Pharmaceuticals.

Dialysis and transplantation in Fabry disease: indications for enzyme replacement therapy.

J. Oliveira, R. Mignani, S. Feriozzi, 2010, Clinical journal of the American Society of Nephrology : CJASN.

The hemolytic uremic syndrome.

G. Remuzzi, P. Ruggenenti, 1985, Kidney international.

Adult nondiarrhea hemolytic uremic syndrome associated with Shiga toxin Escherichia coli O157:H7 bacteremia and urinary tract infection.

G. Remuzzi, P. Ruggenenti, M. Fusaroli, 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

A German outbreak of haemolytic uraemic syndrome

G. Remuzzi, P. Ruggenenti, 2011, The Lancet.

The pathophysiology and management of thrombotic thrombocytopenic purpura

G. Remuzzi, P. Ruggenenti, 1996, European journal of haematology.

Bilateral nephrectomy stopped disease progression in plasma-resistant hemolytic uremic syndrome with neurological signs and coma.

G. Remuzzi, M. Salvadori, G. Rizzoni, 1996, Kidney international.

The hemolytic uremic syndrome.

G. Remuzzi, P. Ruggenenti, 2005, Kidney international. Supplement.

Decision time for pancreatic islet-cell transplantation

G. Remuzzi, A. Remuzzi, P. Ruggenenti, 2008, The Lancet.

Rituximab in idiopathic membranous nephropathy: a one-year prospective study.

G. Remuzzi, P. Ruggenenti, A. Perna, 2003, Journal of the American Society of Nephrology : JASN.

Daily renal hypoperfusion induced by cyclosporine in patients with renal transplantation.

N. Perico, G. Remuzzi, A. Benigni, 1992, Transplantation.

TRANSPLANTS

N. Perico, G. Remuzzi, P. Ruggenenti, 1968, Rivista dell'infermiere.

Basiliximab combined with low-dose rabbit anti-human thymocyte globulin: a possible further step toward effective and minimally toxic T cell-targeted therapy in kidney transplantation.

G. Remuzzi, I. Codreanu, P. Ruggenenti, 2006, Clinical journal of the American Society of Nephrology : CJASN.

Paricalcitol for secondary hyperparathyroidism in renal transplantation.

N. Perico, G. Remuzzi, F. Gaspari, 2015, Journal of the American Society of Nephrology : JASN.

CHAPTER 28 – Thrombotic Microangiopathies, Including Hemolytic Uremic Syndrome

G. Remuzzi, P. Ruggenenti, P. Cravedi, 2010 .

Albuminuria Regression in Diabetes: A Therapeutic Target for Nephro- and Cardio-Protection, in Clinics and Research

G. Remuzzi, P. Ruggenenti, 2019, American Journal of Nephrology.

Dual renin-angiotensin system blockade for nephroprotection.

P. Ruggenenti, 2017, Nephrologie & therapeutique.

Dual Renin-Angiotensin System Blockade for Nephroprotection: Still under Scrutiny

G. Remuzzi, P. Ruggenenti, G. Gentile, 2014, Nephron.

Dual RAS blockade—controversy resolved

G. Remuzzi, P. Ruggenenti, 2013, Nature Reviews Nephrology.

Efficacy and Safety of Rituximab Second-Line Therapy for Membranous Nephropathy: A Prospective, Matched-Cohort Study

G. Remuzzi, M. Marasà, P. Ruggenenti, 2011, American Journal of Nephrology.

Low‐Dose Rituximab for Posttransplant Recurrent Membranous Nephropathy

G. Remuzzi, P. Ruggenenti, P. Cravedi, 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

QTc prolongation: methadone's effi cacy-safety paradox

G. Remuzzi, P. Ruggenenti, M. Negri, 2006 .

The renoprotective action of angiotensin-converting enzyme inhibitors in diabetes.

G. Remuzzi, P. Ruggenenti, 1996, Experimental nephrology.

Unrecognized pattern of von Willebrand factor abnormalities in hemolytic uremic syndrome and thrombotic thrombocytopenic purpura.

G. Remuzzi, A. Benigni, P. Ruggenenti, 1999, Journal of the American Society of Nephrology : JASN.

Thrombotic microangiopathies in the intensive care unit: many questions, some answers.

G. Remuzzi, P. Ruggenenti, C. Aros, 2001, Contributions to nephrology.

Safety of Iohexol Administration to Measure Glomerular Filtration Rate in Different Patient Populations: A 25-Year Experience

N. Perico, G. Remuzzi, F. Gaspari, 2018, Nephron.

35-1 Microvascular and Macrovascular Diseases of the Kidney

P. Ruggenenti, P. Cravedi, 2015 .

Liver-kidney transplantation to cure atypical hemolytic uremic syndrome.

G. Remuzzi, P. Ruggenenti, J. Saland, 2009, Journal of the American Society of Nephrology : JASN.

Sirolimus for calcineurin inhibitors in organ transplantation: contra.

G. Remuzzi, P. Ruggenenti, P. Cravedi, 2010, Kidney international.

Islet transplantation: need for a time-out?

G. Remuzzi, A. Remuzzi, P. Ruggenenti, 2008, Nature Clinical Practice Nephrology.

Predicting Cisplatin-Induced Acute Kidney Injury by Urinary Neutrophil Gelatinase-Associated Lipocalin Excretion: A Pilot Prospective Case-Control Study

R. Labianca, N. Perico, G. Remuzzi, 2010, Nephron Clinical Practice.

Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial

G. Remuzzi, B. Ene-Iordache, P. Ruggenenti, 2005, The Lancet.

Rituximab for idiopathic membranous nephropathy

G. Remuzzi, P. Ruggenenti, M. Abbate, 2002, The Lancet.

von Willebrand factor cleaving protease (ADAMTS13) is deficient in recurrent and familial thrombotic thrombocytopenic purpura and hemolytic uremic syndrome.

N. Perico, G. Remuzzi, P. Mannucci, 2002, Blood.

von Willebrand factor cleaving protease (ADAMTS13) is deficient in recurrent and familial thrombotic thrombocytopenic purpura and hemolytic uremic syndrome.

N. Perico, G. Remuzzi, P. Mannucci, 2002, Blood.

Pathophysiology and management of thrombotic microangiopathies.

G. Remuzzi, P. Ruggenenti, 1998, Journal of nephrology.

A cathepsin‐like cysteine proteinase proaggregating activity in thrombotic thrombocytopenic purpura

T. Barbui, P. Ruggenenti, A. Falanga, 1991, British journal of haematology.

Enhanced proteolysis of plasma von Willebrand factor in thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome.

G. Remuzzi, T. Barbui, P. Ruggenenti, 1989, Blood.

Effects of verapamil added-on trandolapril therapy in hypertensive type 2 diabetes patients with microalbuminuria: the BENEDICT-B randomized trial

G. Remuzzi, B. Ene-Iordache, F. Gaspari, 2011, Journal of hypertension.

Hyperhomocysteinemia and increased risk of retinopathy: a cross-sectional, case-control study in patients with type 2 diabetes.

B. Dimitrov, G. Remuzzi, P. Ruggenenti, 2002, Diabetes care.

Fresh lemon juice supplementation for the prevention of recurrent stones in calcium oxalate nephrolithiasis: A pragmatic, prospective, randomised, open, blinded endpoint (PROBE) trial

G. Remuzzi, P. Brambilla, M. Trillini, 2021, EClinicalMedicine.

Thrombotic microangiopathy: E. coli O104:H4 German outbreak: a missed opportunity

G. Remuzzi, P. Ruggenenti, 2012, Nature Reviews Nephrology.

Refractory focal segmental glomerulosclerosis in the adult: complete and sustained remissions of two episodes of nephrotic syndrome after a single dose of rituximab

M. Marasà, P. Ruggenenti, P. Cravedi, 2014, BMJ Case Reports.

Morphofunctional Effects of C5 Convertase Blockade in Immune Complex-Mediated Membranoproliferative Glomerulonephritis: Report of Two Cases with Evidence of Terminal Complement Activation

G. Remuzzi, E. Daina, P. Ruggenenti, 2020, Nephron.

Full-dose NSAIDs at the first sign of respiratory infection? – Authors’ reply

N. Perico, G. Remuzzi, P. Ruggenenti, 2022, The Lancet. Infectious diseases.

Renal function at hospital admission as a prognostic factor in adult hemolytic uremic syndrome. The Italian Registry of Haemolytic Uremic Syndrome.

G. Remuzzi, P. Ruggenenti, P. Zucchelli, 1992, Journal of the American Society of Nephrology : JASN.

Epidemiology of the hemolytic uremic syndrome.

G. Remuzzi, M. Osterholm, P. Ruggenenti, 1991, The New England journal of medicine.

Preliminary results of intrathymic injection of donor cells to prevent acute rejection in human heart transplantation.

N. Perico, G. Remuzzi, M. Senni, 1995, Journal of the American Society of Nephrology : JASN.

Invited letter in response to: “Is the kidney donor profile index (KDPI) universal or UNOS‐specific?”

G. Remuzzi, P. Ruggenenti, 2018, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Failure to predict cyclosporine area under the curve using a limited sampling strategy.

N. Perico, G. Remuzzi, F. Gaspari, 1993, Kidney international.

Data on the assessment of LV mechanics by speckle tracking echocardiography in ADPKD patients

G. Remuzzi, B. Trimarco, P. Ruggenenti, 2018, Data in brief.

Ofatumumab for multirelapsing membranous nephropathy complicated by rituximab-induced serum-sickness

G. Remuzzi, P. Ruggenenti, M. A. Podestà, 2020, BMJ Case Reports.

Kidney Transplantation in Patients With Atypical Hemolytic Uremic Syndrome: A Therapeutic Dilemma (or Not)?

G. Remuzzi, P. Ruggenenti, M. Noris, 2017, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Perioperative Minimal Induction Therapy: A Further Step toward More Effective Immunosuppression in Transplantation

G. Remuzzi, M. Marasà, P. Ruggenenti, 2012, Journal of transplantation.

Continuum of renoprotection with Losartan at all stages of type 2 diabetic nephropathy: A post hoc analysis of the RENAAL trial results: A post hoc analysis of the RENAAL trial results

B. Dimitrov, B. Brenner, G. Remuzzi, 2004 .

Cyclosporine Prolongs Delayed Graft Function in Kidney Transplantation: Are Rabbit Anti-Human Thymocyte Globulins the Answer?

G. Remuzzi, I. Codreanu, P. Ruggenenti, 2005, Nephron Clinical Practice.

Effects of rituximab on morphofunctional abnormalities of membranous glomerulopathy.

G. Remuzzi, F. Gaspari, P. Ruggenenti, 2008, Clinical journal of the American Society of Nephrology : CJASN.

Sexual dimorphic response to rituximab treatment: A longitudinal observational study in a large cohort of patients with primary membranous nephropathy and persistent nephrotic syndrome

G. Remuzzi, P. Ruggenenti, A. Perna, 2022, Frontiers in Pharmacology.

Accelerating the Depletion of Circulating Anti-Phospholipase A2 Receptor Antibodies in Patients with Severe Membranous Nephropathy: Preliminary Findings with Double Filtration Plasmapheresis and Ofatumumab

G. Remuzzi, P. Ruggenenti, M. A. Podestà, 2019, Nephron.

Development Donor-Specific Anti-HLA Antibody Associates with a High Incidence of De Novo Depletion and Regeneration , Which Anti-Thymocyte Globulin Induces B Cell but Not Basiliximab / Low-Dose Rabbit In Kidney Transplant Patients , Alemtuzumab

N. Perico, G. Remuzzi, F. Gaspari, 2013 .

How should patients with, or at risk of, cardiovascular disease be screened for chronic kidney disease?

G. Remuzzi, P. Ruggenenti, 2007, Nature Clinical Practice Nephrology.

Mycophenolate Mofetil Versus Azathioprine in Organ Transplantation

G. Remuzzi, P. Ruggenenti, A. Perna, 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

ABCB1 genotypes predict cyclosporine-related adverse events and kidney allograft outcome.

N. Perico, G. Remuzzi, M. Salvadori, 2009, Journal of the American Society of Nephrology : JASN.

Proteinuria: Increased angiotensin-receptor blocking is not the first option

G. Remuzzi, P. Ruggenenti, P. Cravedi, 2009, Nature Reviews Nephrology.

Idiopathic membranous nephropathy: back to the future?

G. Remuzzi, P. Ruggenenti, 2013, The Lancet.

Hemolytic Uremic Syndrome: A Fatal Outcome after Kidney and Liver Transplantation Performed to Correct Factor H Gene Mutation

N. Perico, G. Remuzzi, J. Platt, 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

α1-antitrypsin therapy in a case of thrombotic thrombocytopenic purpura

P. Mannucci, A. Benigni, P. Ruggenenti, 1995, The Lancet.

Kidney Transplantation From a Donor With Acute Kidney Injury: An Unexpected Outcome

G. Remuzzi, P. Ruggenenti, M. Noris, 2014, American Journal of Transplantation.

Circulating anti-PLA2R autoantibodies to monitor immunological activity in membranous nephropathy.

G. Remuzzi, P. Ruggenenti, P. Cravedi, 2011, Journal of the American Society of Nephrology : JASN.

Rituximab for membranous nephropathy and immune disease: less might be enough

G. Remuzzi, P. Ruggenenti, P. Cravedi, 2009, Nature Clinical Practice Nephrology.

A First Step toward a New Approach to Treating Membranous Nephropathy.

G. Remuzzi, P. Ruggenenti, 2019, The New England journal of medicine.

Pathogenesis and treatment of thrombotic microangiopathy.

G. Remuzzi, P. Ruggenenti, J. Lutz, 1997, Kidney international. Supplement.

Thrombotic microangiopathy following organ transplantation

P. Ruggenenti, 2003 .

Microvascular and Macrovascular Diseases of the Kidney

G. Remuzzi, P. Ruggenenti, P. Cravedi, 2011 .

Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial

G. Remuzzi, F. Gaspari, P. Ruggenenti, 1998, The Lancet.

Phosphate may promote CKD progression and attenuate renoprotective effect of ACE inhibition.

G. Remuzzi, C. Zoccali, P. Ruggenenti, 2011, Journal of the American Society of Nephrology : JASN.

Iohexol plasma clearance for measuring glomerular filtration rate in clinical practice and research: a review. Part 1: How to measure glomerular filtration rate with iohexol?

G. Remuzzi, E. Schaeffner, A. Christensson, 2016, Clinical kidney journal.

Tackling the Shortage of Donor Kidneys: How to Use the Best that We Have

N. Perico, G. Remuzzi, P. Ruggenenti, 2003, American Journal of Nephrology.

Rituximab in idiopathic membranous nephropathy.

G. Remuzzi, F. Gaspari, M. Marasà, 2012, Journal of the American Society of Nephrology : JASN.

Severe early acute humoral rejection resulting in allograft loss in a renal transplant recipient with Campath-1H induction therapy.

G. Remuzzi, P. Ruggenenti, E. Gagliardini, 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

SARS-CoV-2 Spike Protein 1 Activates Microvascular Endothelial Cells and Complement System Leading to Platelet Aggregation

G. Remuzzi, A. Benigni, P. Ruggenenti, 2022, Frontiers in Immunology.

The patient with diabetes mellitus

P. Ruggenenti, L. Gnudi, G. Gentile, 2018 .

Malignant vascular disease of the kidney: nature of the lesions, mediators of disease progression, and the case for bilateral nephrectomy.

G. Remuzzi, P. Ruggenenti, 1996, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Drug-Induced Thrombotic Microangiopathy

G. Remuzzi, P. Ruggenenti, R. Pisoni, 2001, Drug safety.

Understanding the nature of renal disease progression.

G. Remuzzi, A. Benigni, P. Ruggenenti, 1997, Kidney international.

Fatty kidney: emerging role of ectopic lipid in obesity-related renal disease.

H. Lamb, V. D’Agati, E. Porrini, 2014, The lancet. Diabetes & endocrinology.

Novel effective drugs for diabetic kidney disease? or not?

G. Remuzzi, P. Ruggenenti, G. Gentile, 2014, Expert opinion on emerging drugs.

Effect of Trandolapril on Regression of Retinopathy in Hypertensive Patients with Type 2 Diabetes: A Prespecified Analysis of the Benedict Trial

G. Remuzzi, B. Ene-Iordache, P. Ruggenenti, 2010, Journal of ophthalmology.

Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial.

P. Ruggenenti, C. Bedrosian, A. Gaber, 2016, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Increased Fragmentation of von Willebrand Factor, Due to Abnormal Cleavage of the Subunit, Parallels Disease Activity in Recurrent Hemolytic Uremic Syndrome and Thrombotic Thrombocytopenic Purpura and Discloses Predisposition in Families

G. Remuzzi, P. Ruggenenti, M. Noris, 1999 .

C5a and C5aR1 are key drivers of microvascular platelet aggregation in clinical entities spanning from aHUS to COVID-19

G. Remuzzi, A. Benigni, P. Ruggenenti, 2021, Blood advances.

Dynamics of complement activation in aHUS and how to monitor eculizumab therapy.

Francesco Tedesco, Giuseppe Remuzzi, Piero Ruggenenti, 2014, Blood.

Ameliorating Hypertension and Insulin Resistance in Subjects at Increased Cardiovascular Risk: Effects of Acetyl-l-Carnitine Therapy

G. Remuzzi, P. Ruggenenti, N. Motterlini, 2009, Hypertension.

Thrombotic microangiopathy in renal transplantation.

G. Remuzzi, P. Ruggenenti, C. Chiurchiu, 2002, Annals of transplantation.

ISN Nexus 2016 Symposia: Translational Immunology in Kidney Disease—The Berlin Roadmap

A. Levin, B. Rovin, G. Remuzzi, 2016, Kidney International Reports.

Sodium intake, ACE inhibition, and progression to ESRD.

Giuseppe Remuzzi, Piero Ruggenenti, Maarten J Postma, 2012, Journal of the American Society of Nephrology : JASN.

Targeting the Renin Angiotensin System in Dialysis Patients

G. Remuzzi, P. Ruggenenti, P. Cravedi, 2011, Seminars in dialysis.

The RAAS in the pathogenesis and treatment of diabetic nephropathy

G. Remuzzi, P. Ruggenenti, P. Cravedi, 2010, Nature Reviews Nephrology.

Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease.

C. Schmid, A. Levey, G. Remuzzi, 2001, Kidney international.

Blood cyclosporine level soon after kidney transplantation is a major determinant of rejection: insights from the Mycophenolate Steroid-Sparing Trial.

B. Dimitrov, N. Perico, G. Remuzzi, 2005, Transplantation proceedings.

The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease.

N. Perico, G. Remuzzi, P. Ruggenenti, 2005, Kidney international. Supplement.

Inhibition of the renin-angiotensin system and cardio-renal protection: focus on losartan and angiotensin receptor blockade

G. Remuzzi, P. Ruggenenti, A. Parvanova, 2005, Expert opinion on pharmacotherapy.

ADAMTS13 Predicts Renal and Cardiovascular Events in Type 2 Diabetic Patients and Response to Therapy

G. Remuzzi, P. Ruggenenti, M. Noris, 2013, Diabetes.

Diagnosis and Prediction of CKD Progression by Assessment of Urinary Peptides.

A. Vlahou, H. Husi, J. Staessen, 2015, Journal of the American Society of Nephrology : JASN.

Estimated GFR: time for a critical appraisal

G. Remuzzi, F. Gaspari, E. Porrini, 2018, Nature Reviews Nephrology.

Iohexol plasma clearance for measuring glomerular filtration rate in clinical practice and research: a review. Part 2: Why to measure glomerular filtration rate with iohexol?

G. Remuzzi, E. Schaeffner, A. Christensson, 2016, Clinical kidney journal.

The GFR and GFR decline cannot be accurately estimated in type 2 diabetics.

G. Remuzzi, Claudia Cella, F. Gaspari, 2013, Kidney international.

Effect of Sirolimus on Disease Progression in Patients with Autosomal Dominant Polycystic Kidney Disease and CKD Stages 3b-4.

L. Antiga, N. Perico, G. Remuzzi, 2016, Clinical journal of the American Society of Nephrology : CJASN.

Glomerular Hyperfiltration and Renal Disease Progression in Type 2 Diabetes

G. Remuzzi, Claudia Cella, F. Gaspari, 2012, Diabetes Care.

Measuring and Estimating GFR and Treatment Effect in ADPKD Patients: Results and Implications of a Longitudinal Cohort Study

N. Perico, G. Remuzzi, B. Ene-Iordache, 2012, PloS one.

Glomerular filtration rate determined from a single plasma sample after intravenous iohexol injection: is it reliable?

N. Perico, G. Remuzzi, F. Gaspari, 1996, Journal of the American Society of Nephrology : JASN.

Chronic kidney disease: Staging CKD: can we rely on estimated GFRs?

G. Remuzzi, P. Ruggenenti, 2011, Nature Reviews Nephrology.

Measurement of GFR with a single intravenous injection of nonradioactive iothalamate.

N. Perico, G. Remuzzi, F. Gaspari, 1992, Kidney international.

Progression, remission, regression of chronic renal diseases

G. Remuzzi, P. Ruggenenti, A. Schieppati, 2001, The Lancet.

Diverse Effects of Increasing Lisinopril Doses on Lipid Abnormalities in Chronic Nephropathies

G. Remuzzi, P. Ruggenenti, A. Perna, 2003, Circulation.

Post-transplant hemolytic-uremic syndrome.

P. Ruggenenti, 2002, Kidney international.

Transplant renal artery stenosis.

G. Remuzzi, P. Ruggenenti, S. Bruno, 2004, Journal of the American Society of Nephrology : JASN.

Eculizumab in patients with severe coronavirus disease 2019 (COVID-19) requiring continuous positive airway pressure ventilator support: Retrospective cohort study

G. Remuzzi, L. Lorini, A. Benigni, 2021, PloS one.

In renal transplantation blood cyclosporine levels soon after surgery act as a major determinant of rejection: insights from the MY.S.S. trial.

B. Dimitrov, N. Perico, G. Remuzzi, 2004, Kidney international.

Treatment of membranous nephropathy: time for a paradigm shift

G. Remuzzi, P. Ruggenenti, F. Fervenza, 2017, Nature Reviews Nephrology.

Epidemiology and outcome - 2

H. Morgenstern, F. Kronenberg, D. Kent, 2009 .

Prevention of Chronic Renal Diseases in the Elderly

N. Perico, G. Remuzzi, P. Ruggenenti, 2008 .

Nonimmunosuppressive therapy of membranous nephropathy.

G. Remuzzi, P. Ruggenenti, A. Perna, 2003, Seminars in nephrology.

Rituximab for idiopathic membranous nephropathy: who can benefit?

G. Remuzzi, P. Ruggenenti, A. Perna, 2006, Clinical journal of the American Society of Nephrology : CJASN.

The role of protein traffic in the progression of renal diseases.

G. Remuzzi, P. Ruggenenti, 2000, Annual review of medicine.

Halting the progression of chronic nephropathy.

G. Remuzzi, P. Ruggenenti, R. Campbell, 2002, Journal of the American Society of Nephrology : JASN.

Rituximab in Primary Membranous Nephropathy: First-Line Therapy, Why Not?

G. Remuzzi, P. Ruggenenti, P. Cravedi, 2014, Nephron Clinical Practice.

The antiproteinuric effect of angiotensin antagonism in human IgA nephropathy is potentiated by indomethacin.

N. Perico, G. Remuzzi, A. Remuzzi, 1998, Journal of the American Society of Nephrology : JASN.

Thrombotic microangiopathies.

G. Remuzzi, P. Ruggenenti, Piero Ruggenenti, 1991, Critical reviews in oncology/hematology.

Ways to Boost Kidney Transplant Viability: A Real Need for the Best Use of Older Donors

N. Perico, G. Remuzzi, P. Ruggenenti, 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Losartan in diabetic nephropathy

N. Perico, G. Remuzzi, P. Ruggenenti, 2004, Expert review of cardiovascular therapy.

Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis

R. Collins, B. Davis, M. Pfeffer, 2021, The Lancet.

Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis

R. Collins, B. Davis, M. Pfeffer, 2021, The Lancet.

Antihypertensive treatment and risk of cancer: an individual participant data meta-analysis

B. Davis, R. Holman, C. Bulpitt, 2021, The Lancet. Oncology.

Monitoring Initial Response to Angiotensin-Converting Enzyme Inhibitor–Based Regimens: An Individual Patient Data Meta-Analysis From Randomized, Placebo-Controlled Trials

G. Remuzzi, L. Irwig, W. Remme, 2010, Hypertension.

Overview of randomised trials of ACE inhibitors

G. Remuzzi, P. Ruggenenti, 2006, The Lancet.

ACE inhibition is renoprotective among obese patients with proteinuria.

G. Remuzzi, C. Zoccali, P. Ruggenenti, 2011, Journal of the American Society of Nephrology : JASN.

Blood pressure-lowering treatment for prevention of major cardiovascular diseases in people with and without type 2 diabetes: an individual participant-level data meta-analysis

B. Davis, R. Holman, P. Whelton, 2022, The lancet. Diabetes & endocrinology.

Which antihypertensive drugs are the most nephroprotective and why?

G. Remuzzi, P. Ruggenenti, P. Cravedi, 2010, Expert opinion on pharmacotherapy.

SARS-CoV-2 Spike Protein 1 Activates Microvascular Endothelial Cells and Complement System Leading to Thrombus Formation

G. Remuzzi, A. Benigni, P. Ruggenenti, 2021, SSRN Electronic Journal.

Mechanisms and treatment of CKD.

G. Remuzzi, P. Ruggenenti, P. Cravedi, 2012, Journal of the American Society of Nephrology : JASN.

Effects of add-on fluvastatin therapy in patients with chronic proteinuric nephropathy on dual renin-angiotensin system blockade: the ESPLANADE trial.

G. Remuzzi, M. Tonelli, B. Ene-Iordache, 2010, Clinical journal of the American Society of Nephrology : CJASN.

The diabetic CKD patient--a major cardiovascular challenge.

G. Remuzzi, I. M. van der Meer, P. Ruggenenti, 2010, Journal of renal care.

Effects of Octreotide–Long-Acting Release Added-on Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease: Pilot, Randomized, Placebo-Controlled, Cross-Over Trial

N. Perico, G. Remuzzi, A. Remuzzi, 2023, Clinical journal of the American Society of Nephrology : CJASN.

Current Status of Islet Transplantation

G. Remuzzi, A. Remuzzi, P. Ruggenenti, 2014 .

Successes and disappointments with clinical islet transplantation.

G. Remuzzi, I. M. van der Meer, P. Ruggenenti, 2010, Advances in experimental medicine and biology.

35th Annual meeting of the European Association for the Study of Diabetes. Brussels, Belgium, 28 September-2 October, 1999. Abstracts.

Thomas J. Smith, B. M. Rasmussen, V. C. Phan, 1999, Diabetologia.

Cost-effectiveness of ACE inhibitor therapy to prevent dialysis in nondiabetic nephropathy: influence of the ACE insertion/deletion polymorphism

S. Vegter, M. Postma, G. Remuzzi, 2009, Pharmacogenetics and genomics.

ACE genotype and ACE inhibitors induced renoprotection in chronic proteinuric nephropathies1.

G. Remuzzi, C. Zoccali, P. Ruggenenti, 2000, Kidney international.

Preventing microalbuminuria in patients with type 2 diabetes

P. Ruggenenti, G. Jermendy, 2007, Diabetes/metabolism research and reviews.

Blood Pressure and Metabolic Effects of Acetyl-l-Carnitine in Type 2 Diabetes: DIABASI Randomized Controlled Trial

G. Remuzzi, F. Gaspari, D. Warnock, 2018, Journal of the Endocrine Society.

Renin-angiotensin system, proteinuria, and tubulointerstitial damage.

G. Remuzzi, P. Ruggenenti, C. Aros, 2001, Contributions to nephrology.

Worsening kidney function in decompensated heart failure: treat the heart, don't mind the kidney.

G. Remuzzi, P. Ruggenenti, 2011, European heart journal.

Retarding progression of chronic renal disease: the neglected issue of residual proteinuria.

G. Remuzzi, P. Ruggenenti, A. Perna, 2003, Kidney international.

Thrombotic thrombocytopenic purpura and related disorders.

G. Remuzzi, P. Ruggenenti, 1990, Hematology/oncology clinics of North America.

Increased fragmentation of von Willebrand factor, due to abnormal cleavage of the subunit, parallels disease activity in recurrent hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and discloses predisposition in families. The Italian Registry of Familial and Recurrent HUS/TTP.

G. Remuzzi, P. Ruggenenti, M. Noris, 1999, Blood.

Hypocomplementemia discloses genetic predisposition to hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: role of factor H abnormalities. Italian Registry of Familial and Recurrent Hemolytic Uremic Syndrome/Thrombotic Thrombocytopenic Purpura.

G. Remuzzi, P. Zipfel, C. Skerka, 1999, Journal of the American Society of Nephrology : JASN.

Heparin in pregnant women with previous placenta-mediated pregnancy complications: a prospective, randomized, multicenter, controlled clinical trial.

G. Remuzzi, G. Pardi, P. Ruggenenti, 2012, Blood.

Chapter 26 – Thrombotic Microangiopathies

G. Remuzzi, P. Ruggenenti, M. Noris, 2008 .

Proteinuria predicting outcome in renal disease: nondiabetic nephropathies (REIN).

G. Remuzzi, P. Ruggenenti, C. Chiurchiu, 2004, Kidney international. Supplement.

Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury.

G. Remuzzi, P. Ruggenenti, A. Perna, 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Octreotide-LAR in later-stage autosomal dominant polycystic kidney disease (ALADIN 2): A randomized, double-blind, placebo-controlled, multicenter trial

N. Perico, G. Remuzzi, A. Remuzzi, 2019, PLoS medicine.

Left ventricular dysfunction in ADPKD and effects of octreotide-LAR: A cross-sectional and longitudinal substudy of the ALADIN trial.

G. Remuzzi, B. Trimarco, P. Ruggenenti, 2019, International journal of cardiology.

The nephropathy of non-insulin-dependent diabetes: predictors of outcome relative to diverse patterns of renal injury.

G. Remuzzi, P. Ruggenenti, A. Perna, 1998, Journal of the American Society of Nephrology : JASN.

Angiotensin-receptor blockers for renal protection in Type 2 diabetes

G. Remuzzi, P. Ruggenenti, M. Macía, 2006 .

Intensive BP Control in Patients with CKD and Risk for Adverse Outcomes

H. Tighiouart, G. Remuzzi, M. Sarnak, 2023, Journal of the American Society of Nephrology : JASN.

Covid-19 and gender: lower rate but same mortality of severe disease in women—an observational study

A. Gavazzi, G. Remuzzi, M. Senni, 2021, BMC Pulmonary Medicine.

Prevention and treatment of diabetic retinopathy: evidence from clinical trials and perspectives.

G. Remuzzi, P. Ruggenenti, P. Cravedi, 2011, Current diabetes reviews.

Kidney failure stabilizes after a two-decade increase: impact on global (renal and cardiovascular) health.

G. Remuzzi, P. Ruggenenti, 2006, Clinical journal of the American Society of Nephrology : CJASN.

Case Report: Tackling Complement Hyperactivation With Eculizumab in Atypical Hemolytic Uremic Syndrome Triggered by COVID-19

G. Remuzzi, P. Ruggenenti, V. Leone, 2022, Frontiers in Pharmacology.

Octreotide Lar in Patients with Autosomal Dominant Polycystic Kidney Disease: From Bench to A Novel Perspective of Therapy

N. Perico, G. Remuzzi, P. Ruggenenti, 2022, Medical Research Archives.

Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial results.

B. Dimitrov, B. Brenner, G. Remuzzi, 2004, Journal of the American Society of Nephrology : JASN.

Effects of valsartan, benazepril and their combination in overt nephropathy of type 2 diabetes: A prospective, randomized, controlled trial

G. Remuzzi, P. Manunta, F. Gaspari, 2019, Diabetes, obesity & metabolism.

Managing hypertension in diabetic patients – focus on trandolapril/verapamil combination

G. Remuzzi, P. Ruggenenti, Sanjib K Sharma, 2007, Vascular health and risk management.

Case Report: Developing Regulatory-compliant Electronic Case Report Forms for Clinical Trials: Experience with The Demand Trial

Andrea Remuzzi, Luca Antiga, Bogdan Ene-Iordache, 2009, J. Am. Medical Informatics Assoc..

Kidney prevention recipes for your office practice.

N. Perico, G. Remuzzi, I. Codreanu, 2005, Kidney international. Supplement.

Renoprotective Therapy in Patients With Nondiabetic Nephropathies

G. Remuzzi, P. Ruggenenti, R. Pisoni, 2012, Drugs.

Prevention of progression and remission/regression strategies for chronic renal disease

P. Ruggenenti, P. Cravedi, 2009 .

Renal and metabolic effects of insulin lispro in type 2 diabetic subjects with overt nephropathy.

G. Remuzzi, B. Ene-Iordache, P. Ruggenenti, 2003, Diabetes care.

Combined kidney and liver transplantation for familial haemolytic uraemic syndrome

G. Remuzzi, P. Ruggenenti, M. Noris, 2002, The Lancet.

ACE inhibition and ANG II receptor blockade improve glomerular size-selectivity in IgA nephropathy.

N. Perico, G. Remuzzi, A. Remuzzi, 1999, American journal of physiology. Renal physiology.

Effect of high dose ramipril with or without indomethacin on glomerular selectivity.

G. Remuzzi, A. Remuzzi, P. Ruggenenti, 2002, Kidney international.

Remission Achieved in Chronic Nephropathy by a Multidrug Approach Targeted at Urinary Protein Excretion

B. Brenner, G. Remuzzi, P. Ruggenenti, 2001, Nephron.

Angiotensin-converting enzyme inhibition and renal protection in nondiabetic patients: the data of the meta-analyses.

G. Remuzzi, P. Ruggenenti, C. Chiurchiu, 2005, Journal of the American Society of Nephrology : JASN.

ACE inhibition and ANG II receptor blockade improve glomerular size-selectivity in IgA nephropathy.

N. Perico, G. Remuzzi, A. Remuzzi, 1999, The American journal of physiology.

MAFLD and Glomerular Hyperfiltration in Subjects with Prediabetes, Visceral Obesity and "Preserved" Kidney Function:A Cross-Sectional Study.

G. Remuzzi, P. Ruggenenti, M. Bennasar-Veny, 2023, Diabetes research and clinical practice.

SaO006INCREASED PRE-GLOMERULAR RESISTANCE AND KIDNEY HYPOPERFUSION MAY SUSTAIN ACCELERATED GFR DECLINE IN HYPERTENSIVE, TYPE 2 DIABETICS WITH NORMAL AND HIGH NORMAL ALBUMINURIA

G. Remuzzi, F. Gaspari, P. Ruggenenti, 2018 .

Glomerular response to hyperglycemia in human diabetic nephropathy.

G. Remuzzi, A. Remuzzi, P. Ruggenenti, 1990, The American journal of physiology.

Risk factors and action thresholds for the novel coronavirus pandemic. Insights from the Italian Society of Nephrology COVID-19 Survey

A. Flammini, E. Mancini, G. Gambaro, 2021, Journal of Nephrology.

Proteinuria in diabetic nephropathy: Treatment and evolution

G. Remuzzi, P. Ruggenenti, R. Campbell, 2003, Current diabetes reports.

The antiproteinuric effect of high-dose ramipril: Still an open question

G. Remuzzi, A. Remuzzi, P. Ruggenenti, 2003 .

Presence of retinopathy and incident kidney and cardiovascular events in type 2 diabetes with normoalbuminuria - A post-hoc analysis of the PRIORITY randomized clinical trial.

T. Hansen, G. Nijpels, F. Rutters, 2023, Journal of diabetes and its complications.

SP415EMPAGLIFLOZIN AND PROGRESSION OF CHRONIC KIDNEY DISEASE IN TYPE 2 DIABETES COMPLICATED BY NEPHROTIC-RANGE PROTEINURIA: INSIGHTS FROM THE EMPA-REG OUTCOME® TRIAL

B. Zinman, C. Wanner, P. Ruggenenti, 2018 .

RAS blockade: Nephroprotection by dual RAS blockade—a welcome back

G. Remuzzi, P. Ruggenenti, 2015, Nature Reviews Nephrology.

Race-free estimated glomerular filtration rate equation in kidney transplant recipients: development and validation study

Byron H. Smith, T. Larson, X. Jouven, 2023, BMJ.

A Home-Treatment Algorithm Based on Anti-inflammatory Drugs to Prevent Hospitalization of Patients With Early COVID-19: A Matched-Cohort Study (COVER 2)

N. Perico, G. Remuzzi, P. Ruggenenti, 2021, Frontiers in Medicine.

A SIMPLE, HOME-THERAPY ALGORYTHM TO PREVENT HOSPITALIZATION OF COVID-19 PATIENTS: A RETROSPECTIVE OBSERVATIONAL MATCHED-COHORT STUDY

N. Perico, G. Remuzzi, Michela Paganini, 2021, medRxiv.

Insulin Resistance and Microalbuminuria

B. Dimitrov, G. Remuzzi, A. Tiengo, 2006, Diabetes.

Failure of prostacyclin to improve peripheral arterial disease in dialysis patients.

G. Remuzzi, P. Ruggenenti, G. Mecca, 1990, Nephron.

Pretreatment blood pressure reliably predicts progression of chronic nephropathies. GISEN Group.

G. Remuzzi, F. Gaspari, P. Ruggenenti, 2000, Kidney international.

alpha 1-Antitrypsin therapy in a case of thrombotic thrombocytopenic purpura.

G. Remuzzi, P. Mannucci, A. Benigni, 1995, Lancet.

Effects of blood pressure lowering on cardiovascular risk according to baseline body-mass index: a meta-analysis of randomised trials

R. Collins, B. Davis, S. Yusuf, 2015, The Lancet.

Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference.

G. Ardissino, V. D’Agati, C. Alpers, 2017, Kidney international.

H. Mischak, G. Navis, A. Ortiz, 2016, BMJ Open.

Iohexol plasma clearance for measuring glomerular filtration rate in clinical practice and research: a review. Part 1: How to measure glomerular filtration rate with iohexol?

G. Remuzzi, E. Schaeffner, A. Christensson, 2016, Clinical kidney journal.

A meta-analysis of GFR slope as a surrogate endpoint for kidney failure

M. Landray, J. Chan, K. Mahaffey, 2023, Nature Medicine.

A simple, home-therapy algorithm to prevent hospitalisation for COVID-19 patients: A retrospective observational matched-cohort study

N. Perico, G. Remuzzi, P. Ruggenenti, 2021, EClinicalMedicine.

Mayo Clinic consensus report on membranous nephropathy: proposal for a novel classification.

J. Lieske, A. Pani, C. Nast, 2023, Kidney international.

Ofatumumab in Rituximab-Resistant and Rituximab-Intolerant Patients With Primary Membranous Nephropathy.

G. Remuzzi, P. Ruggenenti, N. Rubis, 2023, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephRopathy in TYpe 2 diabetic patients with normoalbuminuria ( PRIORITY )

H. Mischak, G. Navis, G. Spasovski, 2018 .

Rituximab in idiopathic membranous nephropathy: a one-year prospective study.

G. Remuzzi, P. Ruggenenti, A. Perna, 2003, Journal of the American Society of Nephrology : JASN.

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial.

Debra F. Weinstein, Michael G. Miller, M. A. Ferreira, 2019, Lancet.

Mechanisms and treatment of CKD.

G. Remuzzi, P. Ruggenenti, P. Cravedi, 2012, Journal of the American Society of Nephrology : JASN.

Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura.

P. Ruggenenti, M. Noris, G. Remuzzi, 2001, Kidney international.

Long-term outcome of renal transplantation from older donors.

B. Dimitrov, G. Remuzzi, P. Ruggenenti, 2006, The New England journal of medicine.

Outcome of renal transplantation from very old donors.

G. Remuzzi, P. Ruggenenti, N. Motterlini, 2009, The New England journal of medicine.

Excellent Survival Using Kidney Transplants From Older Donors

G. Remuzzi, B. Ene-Iordache, P. Ruggenenti, 2022 .

Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial

L. Antiga, N. Perico, G. Remuzzi, 2013, The Lancet.

Safety and Preliminary Efficacy of Mesenchymal Stromal Cell (ORBCEL-M) Therapy in Diabetic Kidney Disease: A Randomized Clinical Trial (NEPHSTROM)

N. Perico, G. Remuzzi, P. Ruggenenti, 2023, Journal of the American Society of Nephrology : JASN.

Phosphate may promote CKD progression and attenuate renoprotective effect of ACE inhibition.

G. Remuzzi, C. Zoccali, P. Ruggenenti, 2011, Journal of the American Society of Nephrology : JASN.

Effects of Manidipine and Delapril in Hypertensive Patients With Type 2 Diabetes Mellitus: The Delapril and Manidipine for Nephroprotection in Diabetes (DEMAND) Randomized Clinical Trial

G. Remuzzi, B. Ene-Iordache, F. Gaspari, 2011, Hypertension.

Mayo Clinic Consensus Report on Membranous Nephropathy: Proposal for a Novel Classification.

A. Pani, C. Nast, P. Ruggenenti, 2023, Mayo Clinic proceedings.

Role of remission clinics in the longitudinal treatment of CKD.

G. Remuzzi, P. Ruggenenti, A. Perna, 2008, Journal of the American Society of Nephrology : JASN.

A Multidrug, Antiproteinuric Approach to Alport Syndrome: A Ten-Year Cohort Study

G. Remuzzi, F. Gaspari, D. Roccatello, 2015, Nephron.

Unrecognized pattern of von Willebrand factor abnormalities in hemolytic uremic syndrome and thrombotic thrombocytopenic purpura.

G. Remuzzi, A. Benigni, P. Ruggenenti, 1999, Journal of the American Society of Nephrology : JASN.

Incidence and clinical predictors of Kaposi's sarcoma among 1721 Italian solid organ transplant recipients: a multicenter study.

L. Naldi, G. Remuzzi, P. Ruggenenti, 2006, European journal of dermatology : EJD.

Vaccination Recommendations in Solid Organ Transplant Adult Candidates and Recipients

P. Ruggenenti, V. Casotti, D. Pinelli, 2023, Vaccines.

A phase I study of autologous mesenchymal stromal cells for severe steroid-dependent nephrotic syndrome

G. Remuzzi, P. Ruggenenti, N. Rubis, 2023, JCI insight.